| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Zinc and zinc transporters are key molecules in malignant progression and might lead to novel strategies for the diagnosis and therapy of breast cancer. In this study, we elucidated the novel mechanism underlying estrogen receptor-positive human breast cancer progression involving zinc and zinc transporters (ZIP6). We also demonstrated that the efficacy of anti-breast cancer drugs was controlled by the regulation of zinc action through ZIP6 without the damage to normal cellular functions. Therefore, we propose to provide novel strategies for therapy of breast cancer using zinc network.
|
